Pmv Pharmaceuticals Stock Book Value Per Share
| PMVP Stock | USD 1.61 0.04 2.55% |
Pmv Pharmaceuticals fundamentals help investors to digest information that contributes to Pmv Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Pmv Stock. The fundamental analysis module provides a way to measure Pmv Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Pmv Pharmaceuticals stock.
| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 4.70 | 2.91 | |
| Tangible Book Value Per Share | 4.70 | 2.91 |
Pmv | Book Value Per Share |
Pmv Pharmaceuticals Company Book Value Per Share Analysis
Pmv Pharmaceuticals' Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
More About Book Value Per Share | All Equity Analysis
Book Value per Share | = | Common EquityAverage Shares |
Current Pmv Pharmaceuticals Book Value Per Share | 3.82 X |
Most of Pmv Pharmaceuticals' fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pmv Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Pmv Book Value Per Share Driver Correlations
Understanding the fundamental principles of building solid financial models for Pmv Pharmaceuticals is extremely important. It helps to project a fair market value of Pmv Stock properly, considering its historical fundamentals such as Book Value Per Share. Since Pmv Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Pmv Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Pmv Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
| Competition |
Pmv Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
In accordance with the recently published financial statements, the book value per share of Pmv Pharmaceuticals is about 3.824 times. This is 324.94% lower than that of the Biotechnology sector and 101.54% lower than that of the Health Care industry. The book value per share for all United States stocks is 99.8% higher than that of the company.
Pmv Book Value Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pmv Pharmaceuticals' direct or indirect competition against its Book Value Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Pmv Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Pmv Pharmaceuticals by comparing valuation metrics of similar companies.Pmv Pharmaceuticals is currently under evaluation in book value per share category among its peers.
Pmv Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Pmv Pharmaceuticals from analyzing Pmv Pharmaceuticals' financial statements. These drivers represent accounts that assess Pmv Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Pmv Pharmaceuticals' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 1.6B | 2.8B | 1.0B | 396.7M | 456.2M | 433.4M | |
| Enterprise Value | 1.7B | 2.4B | 881.4M | 302.4M | 347.7M | 330.3M |
Pmv Fundamentals
| Return On Equity | -0.24 | ||||
| Return On Asset | -0.2 | ||||
| Current Valuation | (86.26 M) | ||||
| Shares Outstanding | 51.75 M | ||||
| Shares Owned By Insiders | 2.30 % | ||||
| Shares Owned By Institutions | 80.89 % | ||||
| Number Of Shares Shorted | 847.18 K | ||||
| Price To Book | 0.42 X | ||||
| EBITDA | (78.88 M) | ||||
| Net Income | (68.96 M) | ||||
| Cash And Equivalents | 277.43 M | ||||
| Cash Per Share | 6.08 X | ||||
| Total Debt | 13.29 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 24.76 X | ||||
| Book Value Per Share | 3.82 X | ||||
| Cash Flow From Operations | (55.66 M) | ||||
| Short Ratio | 4.16 X | ||||
| Earnings Per Share | (1.00) X | ||||
| Price To Earnings To Growth | (0.31) X | ||||
| Target Price | 5.8 | ||||
| Number Of Employees | 63 | ||||
| Beta | 1.48 | ||||
| Market Capitalization | 83.31 M | ||||
| Total Asset | 252.15 M | ||||
| Retained Earnings | (310 M) | ||||
| Working Capital | 193.38 M | ||||
| Net Asset | 252.15 M |
About Pmv Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pmv Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pmv Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pmv Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Pmv Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Pmv Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Pmv Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Pmv Stock
| 0.67 | MTEM | Molecular Templates | PairCorr |
| 0.65 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.64 | ME | 23Andme Holding | PairCorr |
| 0.58 | TPST | Tempest Therapeutics | PairCorr |
| 0.54 | A | Agilent Technologies Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to Pmv Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Pmv Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Pmv Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Pmv Pharmaceuticals to buy it.
The correlation of Pmv Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Pmv Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Pmv Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Pmv Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Pmv Stock Analysis
When running Pmv Pharmaceuticals' price analysis, check to measure Pmv Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pmv Pharmaceuticals is operating at the current time. Most of Pmv Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Pmv Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pmv Pharmaceuticals' price. Additionally, you may evaluate how the addition of Pmv Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.